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Immunosuppression therapy following organ trans-
plantation is a significant factor in the development
and progression of Kaposi’s sarcoma-associated
herpesvirus (KSHV)-induced posttransplant Kapo-
si’s sarcoma (KS). Switching from cyclosporine to
themTOR inhibitor rapamycin is reported to promote
KS regression without allograft rejection. Examining
the underlying molecular basis for this clinical obser-
vation, we find that KSHV infection selectively upre-
gulates mTOR signaling in primary human lymphatic
endothelial cells (LECs), but not blood endothelial
cells (BECs), and sensitizes LECs to rapamycin-
induced apoptosis. Viral transcriptome analysis re-
vealed that while infected BECs display conventional
latency, KSHV-infected LECs support a radically
different program involving widespread deregulation
of both latent and lytic genes. ORF45, a lytic gene
selectively expressed in infected LECs, is required
for mTOR activation and critical for rapamycin sensi-
tivity. These studies reveal the existence of a unique
herpesviral gene expression program corresponding
to neither canonical latency nor lytic replication, with
important pathogenetic and therapeutic conse-
quences.
INTRODUCTION
Kaposi’s sarcoma (KS), the most common neoplasm in
untreated AIDS patients (Dezube, 1996), is an opportunistic
tumor that can arise from endothelium infected with Kaposi’s
sarcoma-associated herpesvirus (KSHV) (Moore and Chang,
1995). The disease presents as highly vascularized proliferative
lesions, typically on the skin, often with accompanying inflam-
matory changes (Ganem, 2010). KS is an indolent condition in
immunocompetent hosts (Brooks, 1986) but is more widespread
and aggressive in states of immune deficiency including organ
transplantation and AIDS (Dezube, 1996).
The principal targets of KSHV infection in KS lesions are
elongated spindle cells thought to be of endothelial origin
because they express multiple endothelial markers (e.g.,Cell HCD31, CD34, CD36) (Boshoff et al., 1995; Ensoli et al., 2001).
Whether these cells originate from infection of lymphatic endo-
thelial cells (LECs) or blood endothelial cells (BECs) has been
controversial. The idea that KS is a malignancy of lymphatic
endothelium gained popularity when spindle cells were found
to stain for LEC-specific markers (vascular endothelial growth
factor 3 [VEGR3], podoplanin, lymphatic vessel endothelial
hyaluronan 1 [LYVE-1], and D2-40) (Weninger et al., 1999).
However, subsequent studies showed that KSHV infection of
primary endothelial cells alters the expression of endothelial
markers in a way that may confound lineage assignment
(Hong et al., 2004; Wang et al., 2004). For example, viral infec-
tion of BECs efficiently induces expression of PROX1 and other
LEC markers (Hong et al., 2004). Conversely, KSHV infection of
LECs can shift their host transcript profile to one exhibiting
BEC-like characteristics (Wang et al., 2004). As such, the endo-
thelial lineage from which KS is derived has remained a matter
of debate.
Immunodeficiency is a major factor in the development of KS
(Beral et al., 1990), and the growth of solid organ transplanta-
tion has led to a rise in cases of posttransplant KS. This has
posed a dilemma for the treating physician: reduction or full
withdrawal of immunosuppressive drugs can lead to KS tumor
regression, but it also also enhances the risk of graft injury or
loss. Recently, it has been documented in renal transplant
recipients with posttransplant KS that switching their immuno-
suppression from traditional cyclosporine therapy to the mTOR
inhibitor rapamycin leads to the regression of their KS lesions
without allograft rejection (Stallone et al., 2005). Although
biopsies of KS tumors show evidence of mTOR pathway acti-
vation (Stallone et al., 2005), it has been unclear if this activa-
tion is truly essential for KS cell survival or if the therapeutic
benefit of rapamycin in this setting is principally due to its
reduced capacity for immune suppression. To better under-
stand the therapeutic action of rapamycin in KS, we have
examined the effect of KSHV infection on mTOR signaling
and rapamycin sensitivity in primary microvascular LECs and
BECs. Our results reveal striking differences in KSHV transcrip-
tion for these two lineages that lead to selective mTOR
signaling and rapamycin sensitivity in endothelial cells of
lymphatic, but not vascular, origin. These phenotypes can be
attributed to the expression of a specific viral gene, ORF45,
only within the context of KSHV infection that is unique to the
LEC lineage, thus providing a molecular link between KSHV
infection and rapamycin sensitivity.ost & Microbe 13, 429–440, April 17, 2013 ª2013 Elsevier Inc. 429
Figure 1. Establishment of LEC.219 and
BEC.219
(A) Bright-field (top 4 panels) and fluorescent
(bottom 2 panels) images of mock- and stably
infected primary dermal LECs and BECs were
taken at 103magnification on a Nikon Eclipse Ti-E
fluorescence microscope. GFP signal (green)
indicates stable rKSHV.219 infection, and GFP +
RFP (yellow) is a marker for cells undergoing lytic
KSHV infection.
(B) Flow cytometry analysis of GFP-expressing
cells (GFP versus FSC-H, left panels) in LEC.219
determines the percentage of cells that are stably
infected, and the RFP signal (RFP versus FSC-H,
right panels) is supposed to reflect lytic cells. See
also Figure S1.
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Differential Rapamycin Sensitivity of KSHV-Infected
LECs and BECs
In this work, we employ the recombinant virus rKSHV.219, which
constitutively expresses green fluorescent protein (GFP) and a
puromycin resistance gene (Vieira and O’Hearn, 2004).
As such, cells latently infected with rKSHV.219 display both
green fluorescence and selectability in puromycin. In addi-
tion, rKSHV.219 harbors a red fluorescent protein (RFP) gene un-
der the control of a viral promoter that is only active during lytic
replication. Primary dermal microvascular LECs and BECs
were infectedwith rKSHV.219 and subjected to twoweeks of pu-
romycin selection to generate the two polyclonal, stably infected
cell lines LEC.219 and BEC.219, respectively. Microscopic ex-
amination of both lines showed that elongated spindling is only
evident with LEC.219 and is not exhibited by BEC.219 upon sta-
ble infection (Figure 1A, top 4 panels). Merged GFP and RFP im-
ages (bottom panels) in Figure 1A showed that all of the infected
cells are stably carrying the rKSHV.219 episome (green) with
what seems to be very low-level RFP expression (yellow). Flow
cytometry analysis of LEC.219 (Figure 1B) and BEC.219 (Fig-
ure S1B) confirmed the stable rKSHV.219 infection with 100%
of the cells being GFP+ (left panels) along with little or no RFP
signal above background (right panels). Another KSHV isolate,
derived from a recombinant bacmid (BAC16) (Brulois et al.,430 Cell Host & Microbe 13, 429–440, April 17, 2013 ª2013 Elsevier Inc.2012), behaved identically following
infection of LECs (Figure S1), indicating
that these phenotypic differences are
not unique to rKSHV.219 and likely reflect
the influence of endothelial lineage on
infection.
Next, we examined the effects of rapa-
mycin treatment on each infected cell
population. The growth curves of mock-
and stably infected LECs and BECs
were plotted over a 3 day time course
during treatment with either dimethyl sulf-
oxide (DMSO) or 10 nM rapamycin (Fig-
ures 2A and 2B). Figure 2A shows that
mock LECs display only minor growth
retardation when cultured in rapamycin(dotted blue line) versus DMSO (solid blue line). Interestingly,
LECs showed a 2-fold reduction in growth rates when infected
with KSHV (solid red line). However, when these cells were
exposed to rapamycin, they showed a dramatic loss of growth;
indeed, by day 3, the infected cell mass in the rapamycin-treated
LEC.219 culture was lower than it was at the onset of the exper-
iment, suggesting that substantial cell death had occurred. By
contrast, BEC cultures behaved very differently (Figure 2B):
infected BECs grew nearly identically to uninfected BECs (solid
lines), and both lines displayed comparable slowing of growth
in the presence of rapamycin (dotted lines).
Bright-field images show that rapamycin treatment of LEC.219
clearly producedmajor cytopathic changes that were not seen in
untreated LEC.219 (Figure 3A). Infected BECs did not display
these morphologic changes, though they clearly grew to a lower
cell density than their LEC counterparts, in keeping with the
growth curves of Figure 2. To see if apoptosis was contributing
to this phenotype, we examined these cultures by western blot-
ting for the apoptotic marker cleaved caspase-3 (Figure 3A, right
panels, and Figure S2). Infected LECs displayed slightly
enhanced cleavage of caspase-3 over uninfected LECs, but
this cleavage was dramatically increased following treatment
with rapamycin. By contrast, infected BECs did not undergo
apoptosis under either condition. These results were confirmed
by TUNEL staining: infected BECs showed no TUNEL staining
in either the presence or absence of rapamycin (Figure 3B,
Figure 2. Rapamycin Causes a Growth
Phenotype in LEC.219 that Is Specific
to rKSHV.219 Infection
(A and B) Mock- and stably infected primary
dermal LECs (A) and BECs (B) were treated with
either DMSO (solid lines) or 10 nM rapamycin
(dotted lines), and their cell densities at days 0, 1,
2, and 3 were determined by the SRB-based
In Vitro Toxicology Assay Kit (Sigma-Aldrich) with
their respective growth curves plotted above. Er-
ror bars represent SD from the mean (n = 3).
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staining after exposure to rapamycin (Figure 3B, top panels).
mTORC1 Is Activated by ERK2/RSK1 Signaling to TSC2
in LEC.219 but Not in BEC.219
Since rapamycin targets themTOR signaling pathway, we exam-
ined the status of this pathway in primary endothelial cells and
its alterations by KSHV infection. mTOR signaling is known to
control cell growth primarily by regulating cap-dependent
translation and ribosome biogenesis through the phosphoryla-
tion of p70 S6K and 4EBP1, respectively, by the raptor-associ-
ated mTOR complex 1 (mTORC1) (Weber and Gutmann, 2012).
Rapamycin binds cytosolic protein FK-binding protein 12
(FKBP12), and the resulting rapamycin-FKBP12 complex inhibits
mTORC1 allosterically (Chung et al., 1992). mTORC1 signaling is
reliably assayed by p70 S6K phosphorylation at residue T389
(Chung et al., 1992). While 4EBP1 phosphorylation can also
indicate mTORC1 signaling status, this response is more vari-
able in cultured cell lines (Choo et al., 2008).
To begin, we examined the state of mTORC1 signaling in
LECs and BECs before and after stable infection with KSHV by
western blot analysis. As shown in Figure 4A, there is an increase
in p70 S6K phosphorylation in LECs upon stable infection that
leads to increased ribosomal protein S6 phosphorylation, while
KSHV infection in BEC does not affect mTORC1 signaling. These
changes were not mirrored by 4EBP1 phosphorylation, which is
known to be a less reliable marker of pathway activation in many
cultured cells (Choo et al., 2008). Similar to BECs, we saw no up-
regulation of p70 S6K or 4EBP1 phosphorylation following stable
KSHV infection of two other lineages of large vessel-derived pri-
mary human endothelial cells, HUVECs (human umbilical vein
endothelial cells) and HAECs (human aortic endothelial cells)
(Figure S3A). Consistent with these observations, KSHV is not
linked to proliferative lesions of large-vessel endothelium in vivo.
Howmight KSHV infection affect mTORC1 pathway activation
in LECs? In most cells, mTORC1 is under negative regulation by
the upstream tuberous sclerosis complex (TSC), specifically the
TSC2 subunit, which acts to control the activity of the mTORC1
regulatory G protein Rheb (Garami et al., 2003). TSC2 is, in turn,
regulated by a number of signaling pathways. These include the
AKT-dependent phosphorylation of TSC2 from the PI3K
pathway along with ERK- and RSK-dependent phosphorylation
of TSC2 from the mitogen-activated protein kinase (MAPK)
pathway (summarized in Figure 4B) (Inoki et al., 2002; Ma
et al., 2005; Potter et al., 2002; Roux et al., 2004). The best-char-Cell Hacterized regulator of TSC2 is phosphorylation by activated AKT
(Huang and Manning, 2009), and some evidence suggests that
KSHV gene products can upregulate AKT (Sodhi et al., 2004;
Tomlinson and Damania, 2004). However, we found no changes
in AKT phosphorylation upon stable KSHV infection of LECs (Fig-
ures 4C, S3B, and S3C). Consistent with this, we observed a lack
of an increase in TSC2 phosphorylation at residue T1462, the
target of AKT (Figures 4C and S3C). The consistent absence of
T1462 phosphorylation upregulation in TSC2 strongly suggests
that the PI3K/AKT pathway does not contribute to the activation
of mTORC1 in LEC.219.
Recent work indicates that two signaling molecules from the
MAPK pathway can also converge on TSC2: (1) activated ERK
protein (typically activated by upstreamMEK) can phosphorylate
TSC2 at S664 (Ma et al., 2005), and (2) activated RSK can
phosphorylate TSC2 at S1798 (Roux et al., 2004). There is
crosstalk between these regulators since activated ERK can
phosphorylate and activate RSK (Figure 4B). Accordingly, exam-
ination of the phosphorylation state of each of these sites
showed clear enhancement of phosphorylation of TSC2 at
S1798 by KSHV infection, while phosphorylation at S664 was
unchanged (Figures 4D and S3C). This strongly suggests RSK
as the regulator responsible for mTORC1 activation in stably
infected LECs. To affirm this, we examined the state of RSK1
activation in LEC.219 by examining its phosphorylation at T573
(C terminus) and T359 and S363 (activation loop); these are
targets of ERK phosphorylation that lead to RSK1 autophos-
phorylation at S380. As shown in Figure 4D, all of these sites
underwent increased phosphorylation in LEC.219, but not
BEC.219, confirming selective RSK activation in LECs by
KSHV infection. Parenthetically, the phosphorylation of eIF4B,
another downstream substrate of RSK1, was also increased in
LEC.219 (Figure 4D).
These results imply that infected LECs should display
upstream activation of MEK and ERK (Figure 4B). Indeed, when
we examined the activation state of ERK in LEC.219 (Figure 4D)
we discovered strongly enhanced phosphorylation of ERK2.
However, neither ERK1 nor MEK displayed activation. Interest-
ingly, there is no change in the ERK-dependent phosphorylation
of TSC2 at S664, suggesting that whatever mechanism activates
ERK2 may alter the substrate preferences of the enzyme in ways
that are not yet understood. Similarly, although activated RSK
was able to phosphorylate TSC2 at S1798 (Figure 4D), we did
not observe phosphorylation of another RSK substrate, raptor
(Carrie`re et al., 2008); how this selectivity is achieved is alsoost & Microbe 13, 429–440, April 17, 2013 ª2013 Elsevier Inc. 431
Figure 3. Rapamycin Induces Infection-Specific Apoptosis in LEC.219 but Not in BEC.219
(A) Bright-field images of mock- and stably infected LECs and BECs treated with either DMSO or 10 nM rapamycin for 3 days were taken at 103magnification on
a Nikon Eclipse Ti-E fluorescence microscope. Cells were harvested, and cell lysates were analyzed by western blotting with the antibodies indicated.
(B) Cells were treated with either DMSO or 10 nM rapamycin for 3 days and then processed for TUNEL staining. Infected cells are GFP-positive (green), and
TUNEL staining is depicted in red. See also Figure S2.
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ulation of mTORC1 signaling by KSHV is being effected through
the release from the TSC2-induced mTORC1 inhibition resulting
from ERK2-mediated activation of RSK1.432 Cell Host & Microbe 13, 429–440, April 17, 2013 ª2013 ElsevierThese findings were all observed with LECs of dermal micro-
vascular origin. We next asked if similar signaling properties ex-
isted among LECs and BECs harvested from lung (another
frequent site of KS involvement). Figure S3D shows that LECsInc.
Figure 4. mTORC1 Is Activated by ERK2/RSK1 Signaling to TSC2 in LEC.219 but Not in BEC.219
(A) The phosphorylation status of relevant signaling pathways was determined by immunoblotting with indicated antibodies. Western blots of the substrates of
mTORC1 signaling, p70 S6K (that phosphorylates S6) and 4EBP1, in mock- and stably infected (inf) LECs and BECs were performed.
(B) The MAPK pathway (MEK/ERK/RSK) and PI3K/AKT pathway converge at TSC2 to regulate mTORC1 signaling.
(C) PI3K/AKT signaling to TSC2 T1462 shows no contribution to the mTORC1 activation in LEC.219.
(D) ERK2/RSK1 signals to TSC2 S1798 in LEC.219 without any contribution from upstream MEK1/MEK2. See also Figure S3.
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parts with respect to infection-induced ERK2, RSK1, and
mTORC1 activation that lead to rapamycin sensitivity, indicating
that these are properties of the lymphatic endothelial lineage
rather than a tissue-specific effect.
LEC.219 Exhibits Dysregulated Lytic Gene Expression
while BEC.219 Is Latent
Like all herpesviruses, KSHV can exist in two alternative tran-
scriptional states upon infection: latency or lytic replication. In
latency, viral gene expression is restricted to only a handful of
viral genes with no production of viral progeny, while lytic repli-
cation involves the expression of all viral genes in a temporally
ordered cascade that leads to the production of infectious
virions and lysis of the host cell (Renne et al., 1996). Latency is
the default pathway of in vitro KSHV infection in most cell types
(Bechtel et al., 2003) but is reversible: lytic replication can be trig-
gered in latently infected cells by treatment with chemicals such
as phorbol esters and histone deacetylase complex (HDAC)
inhibitors or by ectopic expression of the viral latent/lytic switch
protein RTA (replication and transcription activator) (Sun et al.,
1998; Yu et al., 1999).
The selective activation of ERK2 and RSK1 by KSHV infection
in LEC.219 is reminiscent of signaling resulting from the expres-
sion of KSHV ORF45 (Kuang et al., 2011, 2008, 2009). However,
ORF45 is known to be a lytic gene (Zhu et al., 1999), and it has
generally been presumed that the default pathway of KSHV
gene expression in cultured cells is latency (Bechtel et al.,Cell H2003). Accordingly, we examined the expression of ORF45 and
several other lytic proteins in LEC.219 and BEC.219 by western
blotting. As shown in Figures 5A and S4A, ORF45 was indeed
selectively expressed during stable KSHV infection in LECs but
not BECs. Moreover, other known lytic proteins, including RTA
and K-bZIP, were also selectively turned on in LEC.219, while
the latency marker LANA (ORF73) was comparably expressed
in both cell lineages (Figures 5A and S4A). Kaposin B, the prod-
uct of a gene expressed at very low levels in latency but strongly
induced in the lytic cycle, is also upregulated in LEC.219 and not
detectable in BEC.219. Again, this pattern of expression was
specific to LECs: stably infected HUVEC and HAEC resembled
the latent BEC.219 cell line when blotted for these samemarkers
(Figure S4B, middle and right panels). Moreover, LECs from lung
showed the same pattern of dysregulated expression of viral
lytic proteins, like their counterparts from the dermis, while
pulmonary BECs again showed strong restriction of lytic protein
expression (Figure S4C).
To examine viral gene expression more comprehensively, the
KSHV transcriptomes in stably infected dermal LECs and BECs
were compared by transcript profiling with a custom genomic
KSHV tiling microarray (Chandriani and Ganem, 2010; Chan-
driani et al., 2010). Consistent with the immunoblotting results
of Figures 5A and S4A–S4C, the viral gene expression profiles
in these stably infected lines are dramatically different:
LEC.219 displays extensive transcription from across much of
the viral genome (Figures 5B and S4D, left and middle panels),
including many known lytic genes, while transcripts detected inost & Microbe 13, 429–440, April 17, 2013 ª2013 Elsevier Inc. 433
Figure 5. LEC.219 Exhibits Extensive Lytic
Gene Expression while BEC.219 Displays
Latent Transcription
(A) Expression of viral proteins was analyzed by
western blotting with indicated antibodies.
(B) Viral gene expression in the stably infected
lines was assessed with our custom KSHV tiling
microarray. The microarray data are ordered by
genome position and displayed for 13,444 unique
probes. Zero transformation of infected hybridi-
zation was performed against uninfected hybridi-
zation, and the color bar indicates the fold change
relative to their mock-infected controls (log2
scale). The blue arrows point out specific hybridi-
zation signals. See also Figure S4.
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latency genes (e.g., ORF71–73) (Figures 5B and S4D, left and
middle panels). The BEC.219 pattern also includes RNAs from
ORF75 and K15 as well as RNAs hybridizing at unannotated se-
quences antisense to the kaposin and microRNA loci; the latter
may be due to nonspecific hybridization to repetitive sequences
in these regions. The previously described transcripts originating
from the puromycin/GFP/RFP cassette insertion site in
rKSHV.219 were also observed in all stably infected samples
and are thought to be artifacts of the inserted cassette (Chan-
driani and Ganem, 2010). Notably, the viral transcriptomes of
the HUVEC.219 and HAEC.219 cell lines more closely resemble
that of BEC.219 (Figure 5B).
To clarify what fraction of the LEC.219 cell population is ex-
pressing these traditionally designated lyticmarkers, immunoflu-
orescence assays (IFA) were performed on LEC.219 and
BEC.219. K-bZIP staining of LEC.219 cells shows that themajor-
ity of the stably infected (GFP+) mass culture exhibits lytic pro-
tein expression while K-bZIP staining is completely absent in
BEC.219 (Figure 6). This observation, coupled with the fact
that LEC.219 cells were selected for continued growth in puro-
mycin for 2 weeks and revealed little RFP expression from
rKSHV.219 (Figure 1), affirms that, as suggested by the array
pattern, the majority of the LEC.219 cells are not in the traditional
lytic cycle that kills cells but are displaying a unique transcrip-
tional program that allows expression of numerous lytic genes
in the context of continued cell survival and proliferation. This
is not to say that some cells in LEC.219 are not undergoing clas-
sical lytic replication. Examination of the culture supernatant
does in fact reveal the presence of infectious virions, as judged
by the ability to transfer GFP expression to naive SLK cells (Fig-
ure S5). Quantitation of virus production from stably infected
dermal and lung LECs and BECs (dLEC/dBEC and lLEC/lBEC)
show supernatant viral titers of 103 infectious units/mL from
the stably infected lymphatic lines; this is over 1,000-fold lower
than the titer expected from a comparable number of lytically
induced Vero or SLK cells (Myoung and Ganem, 2011a; Vieira434 Cell Host & Microbe 13, 429–440, April 17, 2013 ª2013 Elsevier Inc.and O’Hearn, 2004). Finally, the fact that
the pattern of transcript accumulation in
LEC.219 is visibly different from that in ly-
tically induced iSLK.219 cells, as judged
by examination on tiling arrays (Fig-
ure S4D, right panel), further supportsthat the predominant program in LEC.219 is not traditional
KSHV lytic replication. Consistent with their latent gene expres-
sion profile, stably infected dermal BECs and lung BECs do not
spontaneously produce any virus (Figure S5).
KSHV ORF45 Is Required for mTORC1 Activation
in LEC.219 and Plays a Key Role in Rapamycin
Sensitivity during Viral Infection
Since ORF45 protein expression is readily detected in LEC.219
(Figures 5A and S4A–S4C), we set out to determine if this lytic
gene is indeed responsible for the signaling observed in LECs
during stable KSHV infection. First, ORF45was stably expressed
in primary dermal LECs by lentiviral transduction, and the state of
mTORC1 signaling in these cells was examined by immunoblot-
ting. Figure 7A shows that isolated ORF45 expression pheno-
copies the signaling phenotype of stable KSHV infection in this
lineage. mTORC1 is activated (increase in p-p70 S6K leading
to increased p-S6), accompanied by evidence of activation of
ERK2 and RSK1 and phosphorylation of TSC2 at T1798. Next,
we asked if small interfering RNA (siRNA)-mediated silencing
of ORF45 in the context of stable KSHV infection would ablate
mTORC1 activation (Figure 7B). LEC.219 cells were transfected
with two different siRNAs directed against ORF45 to produce
strong reductions in the levels of ORF45 protein in the cells
compared to control siRNAs (Kuang et al., 2009). As expected,
this resulted in loss of ERK2 and RSK1 activation, with loss of
TSC2 phosphorylation at S1798 activation and corresponding
loss of the signature of mTORC1 activation: increased phos-
phorylation of p70 S6K and accumulation of p-S6. These results
firmly establish that the dysregulated expression of lytic gene
ORF45 is the principal driver of mTORC1 activation in KSHV-in-
fected LECs.
To explore the relationship between ORF45 expression and
rapamycin sensitivity, uninfected primary LECs expressing only
ORF45 and stably infected LEC.219 were treated with either
DMSO or rapamycin and assayed for apoptosis. Figures 7D
and S6B show that, as expected, there is induction of apoptosis
Figure 6. TheMajority of LEC.219 Cells Are Displaying Dysregulated
Lytic Protein Expression
K-bZIP staining of LEC.219 (top panels) reveals that the majority of stably
infected LECs are displaying dysregulated lytic protein expression, while the
lack of K-bZIP staining in BEC.219 (bottom panels) confirms its latency. The
individual signals for GFP (left panels) and K-bZIP (middle panels) are in black
and white while GFP and nuclear K-bZIP staining is green and blue, respec-
tively, in the merged images (right panels). See also Figure S5.
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expression was knocked down in LEC.219, these infected cells
became less sensitive to rapamycin-induced apoptosis, as re-
flected by significantly less cleaved caspase-3 (Figures 7D and
S6B) and cleaved poly(ADP-ribose) polymerase (PARP) (Fig-
ure 7D). Thus, ORF45 expression is a key driver of rapamycin
sensitivity in KSHV-infected LECs. However, when we examined
uninfected LECs stably transduced with ORF45 expression, a
strikingly different result was observed. As shown in Figure 7C,
even though clear activation of mTORC1 signaling was evident
(and 10 nM rapamycin is able to abolish this signaling), rapamy-
cin treatment did not trigger enhanced apoptosis, as judged by
immunoblotting for cleaved caspase-3 (no change in upper
p19 band and absence of lower p17 cleavage product) and
cleaved PARP (Figure 7C). ORF45-transduced BECs also
behaved similarly (Figure S6A). Taken together, these results
indicate that while ORF45 expression in LEC.219 is necessary
for rapamycin sensitivity, ORF45 expression alone in uninfected
LECs is not sufficient for rapamycin sensitivity.
DISCUSSION
The significance of mTORC1 signaling in KSHV biology came to
the forefront when the mTORC1 inhibitor rapamcyin was shown
to contribute to the regression of KS lesions in renal transplant
patients affected by posttransplant KS (Stallone et al., 2005).
The initial aim of this study was to set up a relevant in vitro cell
culture model to aid in the elucidation of the mechanism of
this therapeutic effect. The key findings of this study are that
(1) stable KSHV infection of primary LECs (but not BECs) sensi-
tizes the infected cells to rapamycin-induced apoptosis, (2) in-
fected LECs exhibit mTORC1 activation while infected BECs
do not, and (3) this differential upregulation of mTORC1 signaling
is a reflection of a much broader dysregulation of viral geneCell Hexpression in LECs not present in BECs, which is still consistent
with cell survival. In this section, we discuss the significance of
these findings and place them in the context of earlier work on
KS and the biology of KSHV in particular and of herpesviruses
in general.
mTOR Signaling and KSHV Infection
Two prior studies have examined the impact of KSHV infection
on signaling pathways that converge on mTOR, though these
were not conducted in primary dermal microvascular endothelial
cells, the cells most relevant to KS. One study described that an
hTERT-immortalized HUVEC cell line stably infected by KSHV
showed mTOR activation that was accompanied by an increase
in PI3K and AKT phosphorylation (Wang and Damania, 2008).
Ectopic expression of the viral proteins K1 and vGPCR has
been shown to activate both PI3K and AKT (Sodhi et al., 2004;
Tomlinson and Damania, 2004), and K1 messenger RNA
(mRNA) was detected in this stably infected HUVEC line (Guilluy
et al., 2011). HUVECs are derived from the endothelium of large
veins and are not thought to be progenitors of KS spindle cells.
We have examined stable KSHV infection of HUVECs, but chose
to use primary cells in our study since immortalization is known
to affect many signaling pathways. In these cells we did not
observe PI3K/AKT/mTOR activation (Figure S3A), and their viral
gene expression profile did not show clear expression of K1 and
vGPCR mRNAs (Figure 5B). We think the differences observed
between these studies are most likely referable to hTERT-medi-
ated immortalization. Notably, we have also studied infection
and mTOR signaling in HAEC, another lineage of endothelium
derived from large vessels. These cells also failed to show infec-
tion-related upregulation of AKT and mTOR signaling (Fig-
ure S3A). The effect of KSHV infection onmTORC1 thus appears
quite specific for the lymphatic endothelial lineage.
The other major published study of KSHV andmTORwas con-
ducted in primary effusion lymphoma (PEL), a tumor of B cell
origin that is also strongly linked to KSHV infection. Interestingly,
PEL cell proliferation was strongly inhibited by rapamycin both
in vitro and after implantation subcutaneously or intraperitoneally
in nude mice (Sin et al., 2007). The effect of rapamycin in these
malignant B cells was largely cytostatic, in contrast to the
apoptotic effects we observed in KSHV-infected LECs. These
data are certainly compatible with KSHV induction of mTORC1
signaling in these B cells. However, since PEL lines are derived
from human patients, no companion isogenic, uninfected B cell
lines exist; thus, it is difficult to say with certainty whether, in
this lineage, mTOR upregulation is directly caused by viral infec-
tion or is due to other signaling changes linked to the trans-
formed phenotype. It is also difficult to make inferences about
endothelial KS lesions using a B cell model.
We did not observe AKT activation in LEC.219 (Figures 4C,
S3B, and S3C) and saw no change in TSC2 phosphorylation at
T1462 (Figures 4C and S3C), the downstream substrate of AKT
that is crucial for the regulation of mTORC1 signaling (Inoki
et al., 2002; Potter et al., 2002). This suggests that AKT signaling
is not the prime driver of mTORC1 activation in these cells.
Rather, the phenotype appears to be related to activation of
ERK/RSK signaling (Figures 4D, S3C, and S3D), another
pathway known to activate mTORC1 through phosphorylation
of a distinct site on TSC2 (S1798) (Roux et al., 2004). Weost & Microbe 13, 429–440, April 17, 2013 ª2013 Elsevier Inc. 435
Figure 7. KSHV ORF45 Is Required for mTORC1 Activation in LEC.219 and Plays a Role in Rapamycin Sensitivity during Viral Infection
(A) KSHV ORF45 was expressed in primary dermal LECs by lentiviral transduction, and immunoblotting of mTORC1 signaling was performed. LECs transduced
with the empty vector were used as the negative control.
(B) Knockdown of ORF45 expression in LEC.219 was accomplished by transient transfection of two different ORF45 siRNAs. Experimental controls include an
untransfected sample and transient transfection of two different negative control siRNAs.
(C) LECs transduced with vector or ORF45 lentivirus were treated with either DMSO or 10 nM rapamycin (Rap) for 3 days.
(D) Mock- and stably infected LECswere each transfected with 10 nMNegative siRNA #2 andORF45 siRNA #1 (2 days) and then treated with either DMSO or Rap
for 3 days. See also Figure S6.
Cell Host & Microbe
Differential KSHV Transcription and mTOR Signalingobserved an imbalanced activation of ERK2 over ERK1, which is
the characteristic signature of a recently described viral activity
of ORF45 (Kuang et al., 2011, 2008, 2009), canonically described
as an immediate-early lytic gene product that has been detected
in KS lesions (Dittmer, 2003; Zhu et al., 1999). ORF45was initially436 Cell Host & Microbe 13, 429–440, April 17, 2013 ª2013 Elsevierdescribed as an inhibitor of IRF7 activation (Zhu et al., 2002),
blunting the induction of type I interferon following infection.
More recently, ORF45 has also been linked to selective upregu-
lation of ERK2 phosphorylation, downstream of MEK, with re-
sulting activation of RSK (Kuang et al., 2011, 2008, 2009); here,Inc.
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Differential KSHV Transcription and mTOR Signalingwe show that this RSK1 activation has the expected conse-
quence on mTORC1 activation. The striking reproduction of
this unusual signaling phenotype in infected LECs, together
with the direct demonstration of ORF45 expression in these
cells, strongly points to ORF45 as the culprit here, an inference
that was directly validated by siRNA-mediated ablation of
ORF45 expression in LEC.219 (Figure 7B).
Stable KSHV infection of LECs not only triggers mTORC1
signaling but also makes these infected cells dependent on
this pathway for their survival since the inhibition of this signaling
by rapamycin triggers apoptosis. In this sense, KSHV-infected
LECs can be said to be addicted to mTORC1 signaling. The
burden of the expanded gene expression program in LEC.219
may be responsible for the difference in proliferation between
mock and infected LECs (Figure 2A), and increased stress result-
ing from this deregulated expression may lead to enhanced
dependence on mTORC1 signaling. Even though ORF45 is
necessary for this addiction (Figures 7D and S6B), its expression
alone in uninfected LECs is not sufficient (Figure 7C). The addic-
tion of LEC.219 to mTORC1 signaling appears to require the
expression of other KSHV genes. Presumably, other viral genes
(and/or host genes regulated by them) may be cooperating with
or linked to ORF45 expression during KSHV infection to make
the cells dependent upon continued mTORC1 activation. The
identification of these genes and the elucidation of their mecha-
nisms will be important subjects for future investigation and can
be expected to shed considerable light on interactions of mTOR
signaling with other cellular processes.
KSHV Gene Expression in Different Endothelial
Lineages
The textbook understanding of herpesvirus gene expression
posits two states, latency and lytic replication. Nuanced variants
on this scheme have been recognized (for example, the recogni-
tion that several different latency programs exist in EBV (Speck
and Ganem, 2010), influenced in part by cell type and other
unknown factors). However, all of these latency programs
involve highly restricted gene expression, and in no case is a
clearly lytic gene expressed.
In the KSHV field, there has been significant suspicion that this
simple model may not always be applicable. It has been sug-
gested that traditional in vitro models of KSHV infection, in which
latency is generally the default pathway, may not reproduce
important features of viral gene expression relevant to KS (Mesri
et al., 2010). There is good evidence that both latent and lytic
gene products may play important roles in KS pathogenesis
(Ganem, 2010; Mesri et al., 2010). While the effects of latent
gene expression on cell survival and signaling have been much
commented upon, there is considerable evidence linking lytic
expression to KS development. For example, lytic replication
leads to paracrine production of factors that can trigger an
inflammatory and angiogenic microenvironment that is thought
to be conducive to KS development (Cesarman et al., 2000).
Lytic replication can also lead to a pool of virus from which
new latently infected cells can be derived (Grundhoff and
Ganem, 2004). Interruption of lytic replication in human hosts
strongly reduces the development of new KS lesions (Martin
et al., 1999). The virus-encoded vGPCR has been long sus-
pected to possibly play an important role in KS pathogenesis,Cell Hbased on the observations that (1) mice expressing a vGPCR
transgene display angioproliferative lesions with some features
of KS (Sodhi et al., 2004) and (2) cultured cells expressing
vGPCR as a single gene display upregulation of VEGF expres-
sion (Bais et al., 1998). vGPCR is a potent signaling molecule
that can upregulate many other molecules that have an impact
on cell survival or inflammation and are implicated in KS,
including NF-kB and p38 (Cannon et al., 2003). However, the
vGPCR is classically annotated as a delayed-early lytic gene
(Arvanitakis et al., 1997), and lytically infected cells strongly
shut off host gene expression and also fail to proliferate (Glaun-
singer and Ganem, 2004). Advocates of the vGPCR’s role in KS
pathogenesis have proposed that perhaps an intermediate state
of viral gene expression might exist in which sporadic lytic genes
can be expressed in the absence of the full lytic program (Mesri
et al., 2010); to date, evidence for such a cycle in human cells has
been lacking. Mouse cells display widespread aberrant KSHV
gene expression following infection (Austgen et al., 2012; Mutlu
et al., 2007), but mice are nonpermissive hosts for KSHV (Aust-
gen et al., 2012); therefore, the relevance of these observations
to humans has been uncertain.
However, the present data indicate that during KSHV infection
in primary human LECs, a genetic program with such formal
properties exists, and evidence of such unique gene expression
in any herpesvirus infection in cells of its native host species is of
significant importance. The spindling exhibited by LEC.219, but
not BEC.219, in Figure 1A is a clue that there may be a difference
in viral gene expression between the two cell lines. Spindling is
due to NF-kB activation, which can be mediated by several viral
proteins (Cannon et al., 2003; Grossmann et al., 2006). Differen-
tial expression of one or more of these proteins may be respon-
sible for this phenotypic difference. However, the lack of RFP
detected in both stably infected LECs and BECs (Figures 1A,
1B, and S1B) would otherwise indicate classic herpesviral
latency in both cell lines, though the expression of RFP from
rKSHV.219 has not always been a faithful marker for lytic replica-
tion (Myoung andGanem, 2011b). This is why it was surprising to
find that LEC.219 displays dysregulated expression of numerous
lytic cycle genes, including RTA, K-bZIP, ORF45, and many
others (Figures 5B and S4D, left and middle panels), in the
context of continued cell survival and proliferation. Possible
evidence of this aberrant program in KS lesions has been sug-
gested by the lack of significant correlation between the pattern
of lytic mRNA levels in KS biopsy specimens and the pattern of
lytic mRNAs in reactivated PEL cells, with the latter following
the highly ordered cascade of gene expression needed for viral
replication (Dittmer, 2011). We emphasize that the existence of
this unique gene expression program does not in itself constitute
evidence for or against a role for the vGPCR in KS development.
The fact that mouse endothelial precursor cells displaying dysre-
gulated KSHV transcription can induce an angioproliferative
lesion in mice establishes that ectopic lytic gene expression
can have a pathologic phenotype with some features of KS
(Mutlu et al., 2007). Our data now show that such a state can
exist in human cells and, in fact, selectively occurs in an endothe-
lial lineage long suspected of playing an important role in KS.
Lastly, we note that KSHV gene expression is not the only
feature affecting the phenotype of microvascular endothelium.
Cheng et al. (2011) have recently shown that KSHV-infectedost & Microbe 13, 429–440, April 17, 2013 ª2013 Elsevier Inc. 437
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embedded in a fibrin matrix, promoted a Notch-induced endo-
thelial-to-mesenchymal transition that is also observed (albeit
at a low frequency) in KS biopsies (Cheng et al., 2011). These
conditions also further upregulated the limited set of lytic genes
that was investigated. Ultimately, the tumorigenic potential of
KSHV may be dependent on both tissue microenvironment
and cell-type specificity.
Implications for Human KS
We emphasize that these results, being the product of an in vitro
system, cannot be rigorously used to produce an unambiguous
model of KS histogenesis in vivo. Certainly, the facts that
(1) transplant-associated KS responds to rapamycin and
(2) KSHV-infected LECs are uniquely sensitized to this drug are
compatible with the idea that KS derives from lymphatic endo-
thelium. However, this conclusion is not absolutely mandated
by our findings. Earlier findings that KSHV infection itself repro-
grams the expression of host lineage markers continue to
confound the issue of lineage origins of KS (Hong et al., 2004;
Wang et al., 2004). However, we note that a recent immunohis-
tochemistry (IHC) study shows that in early (patch/plaque) KS
lesions, cells with the properties of infected LECs (LANA+,
LYVE1+, CD34) represented 20% of all spindle cells in the
lesion, indicating that infected LECs are not rare in vivo, at least
during the early stages of KS (Pyakurel et al., 2006). If these
infected LECs exhibit viral gene expression similar to that
observed in LEC.219, early KS hyperplasia could be promoted
through both cell-autonomous and paracrinemechanismsmedi-
ated by these cells. In the later (nodular) stages, such cells were
much less frequent (<3%). This could indicate that such cells are
negatively selected against (e.g., by cell-mediated immune
responses) or are at a growth disadvantage (entirely consistent
with their slower growth in culture upon infection; Figure 2A). It
is also possible that these cells give rise to the later, more domi-
nant cell type (LANA+ cells expressing both BEC and LEC
markers) through reprogramming. Clearly, more work will need
to be done to determine the role of infected lymphatic endothe-
lium in the natural history of KS in vivo, but this will not be a sim-
ple task, given the absence of any relevant animal models for this
complex angioproliferative and inflammatory state.
Finally, we note that the fact that LECs can be sensitized to
rapamycin-mediated killing by KSHV infection raises the possi-
bility that the observed therapeutic effects of the drug in post-
transplant KS may not be due solely to its reduced capacity for
immune suppression. If so, then rapamycin and its congeners
may find use in the treatment of other forms of KS, including
the classical form unlinked to immune deficiency.
EXPERIMENTAL PROCEDURES
Cell Culture
LECs, BECs, HUVECs, and HAECs were purchased from Lonza and cultured
in EBM-2 media supplemented with either the EGM-2 MV bullet added
for microvascular cells (LECs and BECs) or the EGM-2 bullet added for macro-
vascular cells (HUVECs and HAECs). SLK cell lines were cultured in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin-streptomycin (Invitrogen). Cells were treated
with Hybri-Max DMSO (Sigma-Aldrich) and InSolution Rapamycin (EMD
Biosciences).438 Cell Host & Microbe 13, 429–440, April 17, 2013 ª2013 ElsevierVirus Preparation and Establishment of Stable Infection
rKSHV.219 stocks were prepared from the iSLK.219 cell line, and stable infec-
tion was established as described in the Supplemental Experimental Proce-
dures (Myoung and Ganem, 2011a). All stably infected primary endothelial
cell lines were selected and maintained with 0.25 mg/mL puromycin
(Invivogen).
Flow Cytometry Analysis
Stably infected cells were subjected to flow cytometry analysis with a FACS-
Calibur or LSRII (BD Biosciences), and the resulting data were analyzed by
FlowJo software. Cells were prepared for flow cytometry analysis by trypsini-
zation and then subjected to fixation with 1% paraformaldehyde (PFA).
Viability Assays
The Sulforhodamine B (SRB)-based In Vitro Toxicology Assay Kit (Sigma-
Aldrich) was used for determining cell density, and the In Situ Cell Death
Detection Kit (Roche) was used for TUNEL staining. Both assays were per-
formed according to the manufacturer’s instructions.
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